This post-hoc analysis, using data from the GLORIA-AF registry, aimed to evaluate the risk of adverse events, primarily the risk of ischaemic stroke, despite anticoagulation in patients with atrial fibrillation. Secondary outcomes were all-cause death, cardiovascular death and myocardial infarction. In this touchCARDIO interview, we speak with Dr Wern Yew Ding (Liverpool Heart and Chest Hospital, Liverpool, UK) to discuss the GLORIA-AF registry and the implications for the management of patients with an increased risk of ischaemic stroke.
The abstract entitled ‘Incidence and risk factors for residual adverse events despite anticoagulation in atrial fibrillation: results from phase II/III of the GLORIA-AF registry’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- How substantial a clinical burden is residual risk of ischaemic stroke in patients with atrial fibrillation (AF) who receive anticoagulation? (0:16)
- What are the aims, design and inclusion criteria of the GLORIA-AF registry? (1:08)
- What independent predictors of residual ischaemic stroke were identified by the GLORIA registry? (1:41)
- What differences were seen between patients treated with nonvitamin K antagonist oral anticoagulants versus vitamin K antagonist? (2:58)
- What were the conclusions of the investigators in terms of risk factors for ischaemic stroke? (3:38)
- What can be done to manage modifiable risk factors that contribute to the risk of ischaemic stroke in these patients? (4:47)
Disclosures: Wern Yew Ding has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Atrial Fibrillation here
